Literature DB >> 7876956

The meaning of life expectancy: what is a clinically significant gain?

D Naimark1, G Naglie, A S Detsky.   

Abstract

Mesh：

Year:  1994        PMID： 7876956     DOI： 10.1007/bf02599016

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  22 in total

1.  Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors.

Authors:  G L Colice
Journal:  Arch Intern Med       Date:  1990-12

2.  In search of Methuselah: estimating the upper limits to human longevity.

Authors:  S J Olshansky; B A Carnes; C Cassel
Journal:  Science       Date:  1990-11-02       Impact factor: 47.728

3.  Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis.

Authors:  T J Jordan; E M Lewit; R L Montgomery; L B Reichman
Journal:  JAMA       Date:  1991-06-12       Impact factor: 56.272

4.  An assessment of clinically useful measures of the consequences of treatment.

Authors:  A Laupacis; D L Sackett; R S Roberts
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

5.  Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.

Authors:  B E Hillner; T J Smith; C E Desch
Journal:  JAMA       Date:  1992-04-15       Impact factor: 56.272

6.  Expected gains in life expectancy from various coronary heart disease risk factor modifications.

Authors:  J Tsevat; M C Weinstein; L W Williams; A N Tosteson; L Goldman
Journal:  Circulation       Date:  1991-04       Impact factor: 29.690

7.  Should patients with Björk-Shiley valves undergo prophylactic replacement?

Authors:  J D Birkmeyer; C A Marrin; G T O'Connor
Journal:  Lancet       Date:  1992-08-29       Impact factor: 79.321

8.  A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

Authors:  J R Beck; J P Kassirer; S G Pauker
Journal:  Am J Med       Date:  1982-12       Impact factor: 4.965

9.  Should all patients with atrial fibrillation be screened with echocardiography?

Authors:  N A Desbiens
Journal:  J Gen Intern Med       Date:  1992 Mar-Apr       Impact factor: 5.128

10.  Fallacy of the five-year survival in lung cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1978-12-21       Impact factor: 91.245
View more
  12 in total

1.  From liver cirrhosis to HCC.

Authors:  Luigi Bolondi; Laura Gramantieri
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 2.  Management of hepatocellular carcinoma.

Authors:  P Fitzmorris; M Shoreibah; B S Anand; A K Singal
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-27       Impact factor: 4.553

Review 3.  Prostate cancer: 2. Natural history.

Authors:  R K Nam; M A Jewett; M D Krahn
Journal:  CMAJ       Date:  1998-09-22       Impact factor: 8.262

4.  Assessing heart disease risk in primary care. Cholesterol lowering should be just one part of a multiple risk factor intervention.

Authors:  T Fahey
Journal:  BMJ       Date:  1998-10-24

5.  A proposal for an additional clinical trial outcome measure assessing preventive effect as delay of events.

Authors:  Per Lytsy; Lars Berglund; Johan Sundström
Journal:  Eur J Epidemiol       Date:  2012-12-07       Impact factor: 8.082

Review 6.  Optimal management of colorectal liver metastases in older patients: a decision analysis.

Authors:  Simon Yang; Shabbir M H Alibhai; Erin D Kennedy; Abraham El-Sedfy; Matthew Dixon; Natalie Coburn; Alex Kiss; Calvin H L Law
Journal:  HPB (Oxford)       Date:  2014-06-24       Impact factor: 3.647

7.  Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.

Authors:  Robert G Gish; Richard S Finn; Jorge A Marrero
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-04

8.  Educating health professionals about drug and device promotion: advocates' recommendations.

Authors:  Peter R Mansfield; Joel Lexchin; Leana S Wen; Luisella Grandori; Christopher P McCoy; Jerome R Hoffman; Joana Ramos; Jon N Jureidini
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

9.  Treatment of high blood pressure and gain in event-free life expectancy.

Authors:  Behrouz Kassaï; Jean-Pierre Boissel; Michel Cucherat; Florent Boutitie; François Gueyffier
Journal:  Vasc Health Risk Manag       Date:  2005

10.  Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey.

Authors:  Rasmus Dahl; Dorte Gyrd-Hansen; Ivar Sønbø Kristiansen; Jørgen Nexøe; Jesper Bo Nielsen
Journal:  BMC Med Inform Decis Mak       Date:  2007-03-29       Impact factor: 2.796
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.